Previous research suggests that GUDCA administration improves obesity and glucolipid metabolism (21), while TCA stimulates secretion of glucagon-like peptide-1(GLP-1) and peptide YY (PYY), enhances satiety, and improves insulin sensitivity (22–24). The gene discussed is INS; the disease is obesity disorder.